Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,878 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Esophageal Diseases Clear all
Completed Phase 1 Interventional

Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer

NCT00701857
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, Pemetrexed, radiation therapy
Drug · Radiation
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Oct 11, 2026, 5:16 AM EDT
Completed Not applicable Interventional

Clinical Utility Evidence for TissueCypher®

NCT05200325
View directory record Official record
Conditions
Gastro-Intestinal Disorder, Barrett Esophagus
Interventions
Educational materials for TissueCypher
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 11, 2026, 5:16 AM EDT
Completed No phase listed Observational

Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study）

NCT04027543
View directory record Official record
Conditions
Radiotherapy Side Effect, Chemotherapy Effect, Oesophageal Carcinoma, Effect of Drugs, Safety Issues
Interventions
Neoadjuvant chemoradiotherapy, Oesophagectomy, Neoadjuvant chemotherapy
Combination Product · Procedure · Drug
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Other
Eligibility
18 Years to 80 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 11, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

NCT00838526
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole ER, Ranitidine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Moline, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 11, 2026, 5:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

RAPA-201 Therapy of Solid Tumors

NCT05144698
View directory record Official record
Conditions
Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Other Specified Sites of Skin, Malignant Melanoma, Esophageal Squamous Cell Carcinoma
Interventions
RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
Biological · Drug
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 11, 2026, 5:16 AM EDT
Recruiting Not applicable Interventional

External UES Band (Shaker Pressure Band) and GERD

NCT05697393
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Shaker Pressure Band
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 11, 2026, 5:16 AM EDT
Completed Not applicable Interventional

The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients

NCT01349309
View directory record Official record
Conditions
Dysphagia
Interventions
Swallowing Exercise Group
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 11, 2026, 5:16 AM EDT
Completed Phase 2 Interventional

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

NCT00137852
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Cisplatin, Irinotecan, Celecoxib, Radiation Therapy, Esophagectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 11, 2026, 5:16 AM EDT
Completed Phase 2Phase 3 Interventional

Biomarkers in Phototherapy of Barrett's Esophagus

NCT00587600
View directory record Official record
Conditions
Barrett's Esophagus, High Grade Dysplasia
Interventions
Photodynamic therapy, radiofrequency ablation of barrett's esophagus
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 11, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

NCT00917462
View directory record Official record
Conditions
Esophageal Cancer, Gastroesophageal Junction Cancer
Interventions
Sorafenib, administered orally, CT/MRI
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 11, 2026, 5:16 AM EDT
Recruiting Phase 1 Interventional

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT05005403
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
Interventions
Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
20
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 11, 2026, 5:16 AM EDT
Completed No phase listed Observational

Risk Factors and Biomarkers for Diagnosis and Treatment of EoE

NCT01988285
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Specimen Collection, Questionnaires
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 11, 2026, 5:16 AM EDT
Terminated Phase 2 Interventional

Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

NCT00258297
View directory record Official record
Conditions
Esophageal Cancer
Interventions
gefitinib, conventional surgery, enzyme inhibitor therapy, neoadjuvant therapy, protein tyrosine kinase inhibitor therapy, surgery
Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2013 · Synced Oct 11, 2026, 5:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

GI Neuromuscular Pathology Prospective Registry

NCT02165059
View directory record Official record
Conditions
Gastroparesis
Interventions
Surgical Full Thickness Biopsy
Procedure
Lead sponsor
Indiana University
Other
Eligibility
6 Months to 90 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 11, 2026, 5:16 AM EDT
Completed Phase 3 Interventional

Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

NCT00171418
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Timeline
2003 – 2005
U.S. locations
2
States / cities
Metairie, Louisiana • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Oct 11, 2026, 5:16 AM EDT
Active, not recruiting Phase 2 Interventional

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

NCT06851559
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
41
States / cities
Little Rock, Arkansas • Chula Vista, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 11, 2026, 5:16 AM EDT
Completed Not applicable Interventional Results available

Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett's Esophagus

NCT04301986
View directory record Official record
Conditions
Barrett Esophagus, GERD
Interventions
Cytosponge, Transnasal Endoscopy (TNE), Esophagogastroduodenoscopy
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 11, 2026, 5:16 AM EDT
Completed Early Phase 1 Interventional

Evaluation of a Miniaturized Microscope Device for the Detection of Barrett's Neoplasia: A Pilot Study

NCT01384227
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Proflavine Hemisulfate
Drug
Lead sponsor
Anandasabapathy, Sharmila, M.D.
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 11, 2026, 5:16 AM EDT
Terminated Not applicable Interventional

Rubber Band Ligation and Mucosectomy for Gastroesophageal Reflux Disease (GERD)

NCT01199679
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Heartburn, Regurgitation, Dyspepsia
Interventions
Mucosectomy, Rubber Band Ligation
Procedure
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 11, 2026, 5:16 AM EDT
Active, not recruiting Phase 4 Interventional

Dupilumab for Eosinophilic Esophagitis With Severe Strictures

NCT06352073
View directory record Official record
Conditions
Eosinophilic Esophagitis, EoE
Interventions
Dupilumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 11, 2026, 5:16 AM EDT
Not listed No phase listed Observational

Development of Novel, Biophysically Designed Fluids for Swallowing Disorders

NCT03131869
View directory record Official record
Conditions
Deglutition Disorders
Interventions
Thickened Beverages Nectar, Thickened Beverage Honey
Other
Lead sponsor
Swallow Solutions
Industry
Eligibility
55 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Madison, Wisconsin • Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 11, 2026, 5:16 AM EDT
Enrolling by invitation Not applicable Interventional

Targeting Hypervigilance and Autonomic Arousal: the Psycho-physiologic Model of Gastroesophageal Reflux Disease (GERD)

NCT04960566
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Cognitive Behavioral Therapy, Sham-SOC Lifestyle Coaching
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 11, 2026, 5:16 AM EDT
Completed No phase listed Observational

WATS3D for the Detection of Esophageal Dysplasia

NCT03008980
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Dysplasia, Esophagus Adenocarcinoma
Interventions
Diagnostic Test
Other
Lead sponsor
CDx Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 11, 2026, 5:16 AM EDT
Completed Not applicable Interventional

Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury

NCT01570842
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Anthropometric measurements, Tissue samples
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 11, 2026, 5:16 AM EDT